Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment.
Author
Yong, CandiceCambron-Mellott, M Janelle
Seal, Brian
Will, Oliver
Maculaitis, Martine C
Clapp, Kelly
Mulvihill, Emily
Cotarla, Ion
Mehra, Ranee
Date
2022-01-15Journal
Patient Preference and aAdherencePublisher
Dove PressType
Article
Metadata
Show full item recordAbstract
Purpose: The approval of immune checkpoint inhibitors for metastatic non-small-cell lung carcinomas (mNSCLC) treatment has presented more care options. Therefore, it is important to identify the benefit-risk trade-offs patients and caregivers are willing to make among potential treatment options. This study quantified the preferences of patients and caregivers for attributes of mNSCLC treatment. Methods: Patients with mNSCLC and caregivers completed an online survey assessing preferences using a discrete choice experiment. Respondents chose between hypothetical treatment profiles, with varying levels for 7 attributes associated with first-line treatment, including overall survival (OS), progression-free survival, select adverse events (AEs), and regimen (caregivers). Hierarchical Bayesian modeling was used to estimate attribute-level preference weights. Results: Patients (n = 308) and caregivers (n = 166) most valued increasing OS from 11 to 30 months, followed by decreasing the risk of a serious AE (grade 3/4) that may lead to hospitalization from 70% to 18%. These attributes were over twice as important to both sets of respondents as the other attributes measured. Patients and caregivers would accept increases in the risks of a serious AE (grade 3/4) from 18% to 70% and all grades nausea from 10% to 69% if OS increased by 16.8 and 4.0 months, respectively. The least valued attributes were all grades of pneumonitis (patients) and all grades of skin rash (caregivers). Conclusion: Patients and caregivers are willing to make trade-offs between efficacy and toxicity and may require up to 1.5 years of increased OS to accept a higher risk of AEs. These results can provide guidance to oncologists when engaging in shared-decision making discussions. © 2022 Yong et al.Rights/Terms
© 2022 Yong et al.Keyword
immune checkpoint inhibitorsmetastases
non-small-cell lung carcinomas
overall survival
patient preference
toxicities
Identifier to cite or link to this item
http://hdl.handle.net/10713/17902ae974a485f413a2113503eed53cd6c53
10.2147/PPA.S338840
Scopus Count
Collections
Related articles
- Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.
- Authors: Srinivas S, Mohamed AF, Appukkuttan S, Botteman M, Ng X, Joshi N, Tsai JH, Fang J, Waldeck AR, Simmons SJ
- Issue date: 2020 Sep
- Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.
- Authors: Liu FX, Witt EA, Ebbinghaus S, DiBonaventura Beyer G, Shinde R, Basurto E, Joseph RW
- Issue date: 2017
- Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
- Authors: Stone RL, Cambron-Mellott MJ, Beusterien K, Maculaitis MC, Ritz S, Mulvihill E, Monberg M, Szamreta EA, Amin S, McLaurin K
- Issue date: 2022 Feb
- Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects.
- Authors: Le H, Ryan K, Wahlstrom SK, Maculaitis MC, Will O, Mulvihill E, LeBlanc TW
- Issue date: 2021
- Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers.
- Authors: Morel T, Aymé S, Cassiman D, Simoens S, Morgan M, Vandebroek M
- Issue date: 2016 May 26